Immunotherapy May Increase the Risk of Treatment Discontinuation in SCLC
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.
Five-year data support the use of pembrolizumab plus pemetrexed-platinum chemotherapy as standard care for previously untreated, metastatic, EGFR/ALK-wild-type NSCLC, according to researchers.
Adding chemotherapy to first-line treatment with gefitinib improves outcomes in patients who have EGFR-mutant non-small cell lung cancer with brain metastases, a phase 3 trial suggests.
Sublobar resection is noninferior for disease-free and overall survival for patients with tumors ≤2 cm.
Targeted therapies are underused in Medicaid patients with EGFR- or ALK-altered, metastatic non-small cell lung cancer, research suggests.
Tumor mutational burden can predict outcomes of chemoradiation plus durvalumab in patients with stage III non-small cell lung cancer, a study suggests.
Domvanalimab-containing treatment regimens may improve outcomes, when compared with zimberelimab alone, in patients with PD-L1-high non-small cell lung cancer.
Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.
Performing liquid biopsy before tissue biopsy reveals more biomarkers in patients with non-small cell lung cancer, a study suggests.